Accurate medicine: Indirect targeting of NPM1-Mutated AML

Christopher Hourigan, Peter D. Aplan

Research output: Contribution to journalArticle

Abstract

Acute myeloid leukemia (AML) is now recognized to be an imprecise term that refers to a range of myeloid malignancies that have different genetical etiologies, clinical characteristics, and therapeutic sensitivities. Targeting the MLL1 and DOT1L histone modification complexes, both alone and in combination, showed activity against AML driven by a mutant NPM1 protein in several preclinical models and may represent a new treatment direction for this devastating disease.

Original languageEnglish (US)
Pages (from-to)1087-1089
Number of pages3
JournalCancer Discovery
Volume6
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Histone Code
Medicine
Mutant Proteins
Neoplasms
Therapeutics
Direction compound

ASJC Scopus subject areas

  • Oncology

Cite this

Accurate medicine : Indirect targeting of NPM1-Mutated AML. / Hourigan, Christopher; Aplan, Peter D.

In: Cancer Discovery, Vol. 6, No. 10, 01.10.2016, p. 1087-1089.

Research output: Contribution to journalArticle

Hourigan, Christopher ; Aplan, Peter D. / Accurate medicine : Indirect targeting of NPM1-Mutated AML. In: Cancer Discovery. 2016 ; Vol. 6, No. 10. pp. 1087-1089.
@article{c0c9d6647bcd4ee5866253e1b23ef53c,
title = "Accurate medicine: Indirect targeting of NPM1-Mutated AML",
abstract = "Acute myeloid leukemia (AML) is now recognized to be an imprecise term that refers to a range of myeloid malignancies that have different genetical etiologies, clinical characteristics, and therapeutic sensitivities. Targeting the MLL1 and DOT1L histone modification complexes, both alone and in combination, showed activity against AML driven by a mutant NPM1 protein in several preclinical models and may represent a new treatment direction for this devastating disease.",
author = "Christopher Hourigan and Aplan, {Peter D.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1158/2159-8290.CD-16-0917",
language = "English (US)",
volume = "6",
pages = "1087--1089",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Accurate medicine

T2 - Indirect targeting of NPM1-Mutated AML

AU - Hourigan, Christopher

AU - Aplan, Peter D.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Acute myeloid leukemia (AML) is now recognized to be an imprecise term that refers to a range of myeloid malignancies that have different genetical etiologies, clinical characteristics, and therapeutic sensitivities. Targeting the MLL1 and DOT1L histone modification complexes, both alone and in combination, showed activity against AML driven by a mutant NPM1 protein in several preclinical models and may represent a new treatment direction for this devastating disease.

AB - Acute myeloid leukemia (AML) is now recognized to be an imprecise term that refers to a range of myeloid malignancies that have different genetical etiologies, clinical characteristics, and therapeutic sensitivities. Targeting the MLL1 and DOT1L histone modification complexes, both alone and in combination, showed activity against AML driven by a mutant NPM1 protein in several preclinical models and may represent a new treatment direction for this devastating disease.

UR - http://www.scopus.com/inward/record.url?scp=84994134185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994134185&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-0917

DO - 10.1158/2159-8290.CD-16-0917

M3 - Article

C2 - 27698101

AN - SCOPUS:84994134185

VL - 6

SP - 1087

EP - 1089

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 10

ER -